Business Wire

Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Earth.com

Vaccine safety study includes 99 million people

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

Tracking health across a lifetime: Northern Finland Birth Cohort 1966 launches new follow-up as participants turn 60

One of the world's most extensive birth cohorts is now entering later adulthood. At the University of Oulu in Finland, the ...
Medical Xpress

Large follow-up study demonstrates long-term benefits of weight-loss surgery in young people

Ten years after undergoing bariatric surgery as teens, over half of study participants demonstrated not only sustained weight loss, but also resolution of obesity-related conditions, such as type 2 ...
Nasdaq

Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study

Biofrontera announced that a key milestone in its Phase 3 study of the use of Ameluz and RhodoLED PDT in the treatment of sBCC was met with the last patient completing the 1 year follow-up visit in ...
Medscape

Study Supports Follow-Up Consultations After Heart Failure

About 40% of patients with diagnosed heart failure did not pursue future cardiology consultations, regardless of the initial severity of their condition. A single ...
The American Journal of Managed Care

Timely Outpatient Follow-Up Reduces Hospital Readmissions

Adequate outpatient follow-up within 30 days significantly reduces 30-day all-cause hospital readmissions, impacting hospital finances and patient care quality. The study analyzed 83 studies, ...
Business Wire

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today ...